Cipla Ltd P/E Ratio

The P/E Ratio of Cipla Ltd is 28.4 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Cipla Ltd changed from 27.9 on March 2019 to 26 on March 2023 . This represents a CAGR of -1.40% over 5 years. a1#The Latest Trading Price of Cipla Ltd is ₹ 1499 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.2 in 5 years. This represents a CAGR of -0.79%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Cipla Ltd changed from ₹ 42645 crore on March 2019 to ₹ 72696 crore on March 2023 . This represents a CAGR of 11.26% over 5 years. a1#The Revenue of Cipla Ltd changed from ₹ 5478 crore to ₹ 6412 crore over 8 quarters. This represents a CAGR of 8.19% a1#The EBITDA of Cipla Ltd changed from ₹ 1246 crore to ₹ 1565 crore over 8 quarters. This represents a CAGR of 12.04% a1#The Net Pr of Cipla Ltd changed from ₹ 706.56 crore to ₹ 934.4 crore over 8 quarters. This represents a CAGR of 15.00% a1#The Dividend Payout of Cipla Ltd changed from 12.8 % on March 2019 to 27.3 % on March 2023 . This represents a CAGR of 16.36% over 5 years. a1#

The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa. In the year 1960, they started operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. The undertaking has a manufacturing facility, approved by US FDA and WHO, for APIs and intermediates. Cipla Medpro South Africa is a leading provider of chronic medicines to the public and private sectors. On 7 July 2014, Cipla announced its intention to make investments of up to 100 million in its UK subsidiary over the next few years. In its bid to enter the markets of Czech Republic and Slovaki, Cipla on 8 September 2014 announced commercial collaboration with UK-based S&D Pharma. On 13 February 2015, Cipla announced that it has been awarded USD 188.95 million of Global Fund ARV Tender for anti-retrovirals drugs. Croatia, Al Jabal For Drugs And Medical Appliances Company Ltd, Yemen, Cipla Agrimed Proprietary Ltd and Cipla Vet Proprietary Ltd., in South Africa. In South Africa, Mirren (Pty) Limited was acquired as a part of strategy to strengthen its OTC portfolio. During the FY2021, the Group has divested its stake in two of its subsidiaries namely Quality Chemical Limited (Group share - 51.18%) and Anmarate Proprietary Limited (wholly owned subsidiary). Cipla Digital Health Limited was incorporated as a wholly owned subsidiary of the Company on 25th February, 2022. It launched ceftazidime-avibactam intravenous formulation (CipCZA) in India, a new treatment to treat bacterial infections. In year 2022-23, the Company acquired 21.05% stake in Achira Labs Private Limited effective on 17th August, 2022.